At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available. 


The value of precision medicine in oncology is becoming more and more important. We now have the first tumor agnostic approvals from the authorities, both FDA and EMA [European Medicines Agency], so we need to set up systems where we can screen patients for different molecular abberations because more and more agents will become available. So we need to have a set up of how to identify these patients.